FDA Authorizes Monthly Olanzapine Injection for Schizophrenia Treatment

The FDA has approved Weltruza (olanzapine), a new long-acting atypical antipsychotic, for the monthly treatment of schizophrenia in adults. This subcutaneous injection offers a new administration option, potentially improving patient adherence and outcomes. A Boxed Warning notes an increased risk of death in elderly patients with dementia-related psychosis, for whom it is not indicated.